AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24473581 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-stigma reduction programme
Number of subjects: 0
Study 24473581 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher global functioning, better readiness for action, and lower self-esteem decrement
Number of subjects: 0
Study 24473581 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesser psychiatric symptoms
Number of subjects: 0
Study 24473581 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-stigmatisation
Number of subjects: 0
Study 20602260 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 60
Study 20602260 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 18784609 — intervention group
Group type: EXPERIMENTAL
Intervention: Maca (3.5 g/day for 6 weeks)
Number of subjects: 14
Study 18784609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for 6 weeks)
Number of subjects: 14
Study 16651830 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drug (T) - oral desmopressin acetate 400 mug
Number of subjects: 60
Study 12021946 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-R15896AR
Number of subjects: 103
Study 12021946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 9683118 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational interleukin-2 (IL-2) therapy
Number of subjects: 50
Study 9683118 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving IL-2)
Number of subjects: 50
Study 9160569 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine (a combined MAO‐A inhibitor/5‐HT transport inhibitor)
Number of subjects: 0
Study 9160569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2742416 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy (delayed loading of radioactive sources after 5 days post-operation)
Number of subjects: 50
Study 2742416 — intervention group
Group type: COMPARATOR
Intervention: No radiation (control group)
Number of subjects: 50
Study 4202265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 229
Study 4202265 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 229
Study 31134657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg, twice daily for 5 days)
Number of subjects: 21
Study 31134657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 26957489 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol endovenous microfoam (PEM 0.5%)
Number of subjects: 117
Study 26957489 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol endovenous microfoam (PEM 1%)
Number of subjects: 117
Study 26957489 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol endovenous microfoam (PEM 0.5% and 1%)
Number of subjects: 117
Study 26957489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 24045099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (3.4±1.1mL/d) for 3 months
Number of subjects: 83
Study 24045099 — intervention group
Group type: COMPARATOR
Intervention: No fish oil (−FO)
Number of subjects: 83
Study 21403974 — intervention group
Group type: EXPERIMENTAL
Intervention: Project P.A.T.H.S. program participants
Number of subjects: 3797
Study 21403974 — intervention group
Group type: EXPERIMENTAL
Intervention: Project P.A.T.H.S. program participants who regarded the program as helpful
Number of subjects: 3797
Study 19910804 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg press exercise
Number of subjects: 30
Study 19910804 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest press exercise
Number of subjects: 30
Study 19910804 — intervention group
Group type: EXPERIMENTAL
Intervention: Lat pull down exercise
Number of subjects: 30
Study 19910804 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 30
Study 17989382 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 2006
Study 17989382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2006
Study 15553345 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention consisting of an information booklet on postnatal depression and an audiotape of one woman's journey through clinical postnatal depression.
Number of subjects: 184
Study 15553345 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 184
Study 11498312 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE(1) at a rate of 0.02 microg/kg/min
Number of subjects: 14
Study 11498312 — intervention group
Group type: COMPARATOR
Intervention: Saline at a rate of 2 mL/min (control group)
Number of subjects: 14
Study 9921700 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI plus buspirone
Number of subjects: 119
Study 9921700 — intervention group
Group type: COMPARATOR
Intervention: SSRI plus placebo
Number of subjects: 119
Study 9921700 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI plus buspirone (open-label poststudy treatment)
Number of subjects: 119
Study 7519866 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 300 mg
Number of subjects: 8
Study 7519866 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 450 mg
Number of subjects: 8
Study 7519866 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 600 mg
Number of subjects: 8
Study 7519866 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (various doses)
Number of subjects: 8
Study 2667326 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alternating with chemotherapy (5-fluorouracil, doxorubicin, mitomycin, and cis-platin)
Number of subjects: 36
Study 2667326 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (5-fluorouracil, doxorubicin, mitomycin, and cis-platin)
Number of subjects: 36
Study 2667326 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alternating with chemotherapy
Number of subjects: 36
Study 2667326 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (Interferon alternating with chemotherapy and Chemotherapy only)
Number of subjects: 36
Study 171057 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy followed by surgery (290 patients)
Number of subjects: 703
Study 171057 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery (278 patients)
Number of subjects: 703
Study 171057 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery after radiotherapy (78 patients)
Number of subjects: 703
Study 171057 — intervention group
Group type: COMPARATOR
Intervention: No surgery (74 patients)
Number of subjects: 703
Study 31221891 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support system (CDSS) for detection of paediatric SIRS; specific dosage and duration not mentioned.
Number of subjects: 300
Study 31221891 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care decisions; specific dosage and duration not mentioned.
Number of subjects: 300
Study 28576452 — intervention group
Group type: EXPERIMENTAL
Intervention: Naldemedine 0.2 mg once a day for 12 weeks
Number of subjects: 1100
Study 28576452 — intervention group
Group type: COMPARATOR
Intervention: Placebo once a day for 12 weeks
Number of subjects: 1100
Study 26323728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5μg/kg/10min infusion
Number of subjects: 60
Study 26323728 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline infusion (Control Group)
Number of subjects: 60
Study 26323728 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 23145864 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacrimal probing and irrigation with adjunctive mitomycin-C (1 mL of 0.2 mg/mL, once)
Number of subjects: 40
Study 23145864 — intervention group
Group type: COMPARATOR
Intervention: Only probing (control)
Number of subjects: 40
Study 21605317 — intervention group
Group type: EXPERIMENTAL
Intervention: Race × physical health (BMI as dependent variable)
Number of subjects: 451
Study 21605317 — intervention group
Group type: EXPERIMENTAL
Intervention: Race × percentage of dietary fat (total dietary kilocalories as dependent variable)
Number of subjects: 451
Study 21605317 — intervention group
Group type: EXPERIMENTAL
Intervention: Race × median income (exercise minutes per week as dependent variable)
Number of subjects: 451
Study 19635606 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha2b (IFN) as an adjuvant to HBV vaccine
Number of subjects: 0
Study 19635606 — intervention group
Group type: COMPARATOR
Intervention: HBV vaccine alone
Number of subjects: 0
Study 17111013 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (1 g.kg body mass(‐1))
Number of subjects: 22
Study 17111013 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-caloric drink)
Number of subjects: 22
Study 17111013 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation
Number of subjects: 22
Study 17111013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16900304 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment (ACT, social skills training, and family intervention)
Number of subjects: 547
Study 16900304 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 547
Study 14620895 — intervention group
Group type: EXPERIMENTAL
Intervention: Echogenic polymer-coated needle
Number of subjects: 61
Study 14620895 — intervention group
Group type: COMPARATOR
Intervention: Untreated needle
Number of subjects: 61
Study 14620895 — intervention group
Group type: COMPARATOR
Intervention: Teflon-coated needle
Number of subjects: 61
Study 14620895 — intervention group
Group type: COMPARATOR
Intervention: Etched tip needle
Number of subjects: 61
Study 11329095 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg
Number of subjects: 179
Study 11329095 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 40 mg
Number of subjects: 179
Study 11329095 — intervention group
Group type: COMPARATOR
Intervention: Fosinopril 1 mg
Number of subjects: 179
Study 11329095 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (20 mg and 40 mg)
Number of subjects: 179
Study 7753432 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmatic beta 2‐microglobulin measurement in group A (microalbuminuria)
Number of subjects: 62
Study 7753432 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmatic beta 2‐microglobulin measurement in group B (normal albuminuria)
Number of subjects: 62
Study 7753432 — intervention group
Group type: COMPARATOR
Intervention: Plasmatic beta 2‐microglobulin measurement in group C (healthy control)
Number of subjects: 62
Study 2191878 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g acetylsalicylic acid (ASA) per day, starting day two prior to surgery
Number of subjects: 66
Study 2191878 — intervention group
Group type: COMPARATOR
Intervention: Control group without antiplatelet medication
Number of subjects: 66
Study 2191878 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g acetylsalicylic acid (ASA) in patients with signs of progression in histopathological examination
Number of subjects: 66
Study 2191878 — intervention group
Group type: COMPARATOR
Intervention: No ASA in patients without signs of cellular infiltration
Number of subjects: 66
Study 76397 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate tablets, 0.6 g daily for 4 weeks
Number of subjects: 26
Study 30781781 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling (Intervention Group)
Number of subjects: 433
Study 30781781 — intervention group
Group type: COMPARATOR
Intervention: Routine counseling (Control Group)
Number of subjects: 433
Study 28335767 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored physical activity intervention
Number of subjects: 77
Study 28335767 — intervention group
Group type: COMPARATOR
Intervention: Standard information group (control)
Number of subjects: 77
Study 25251189 — intervention group
Group type: EXPERIMENTAL
Intervention: High COHb (≥4 g·dl(‐1))
Number of subjects: 100
Study 25251189 — intervention group
Group type: COMPARATOR
Intervention: Low COHb (≤3 g·dl(‐1))
Number of subjects: 100
Study 22584071 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 105
Study 22584071 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care (by age 2)
Number of subjects: 105
Study 22584071 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care (by age 1; 3)
Number of subjects: 105
Study 22584071 — intervention group
Group type: COMPARATOR
Intervention: Institutional care
Number of subjects: 105
Study 21745769 — intervention group
Group type: EXPERIMENTAL
Intervention: Products containing sodium hypochlorite, ammonia, and triclosan used in the kitchen and bathroom for one month.
Number of subjects: 32
Study 21745769 — intervention group
Group type: COMPARATOR
Intervention: Usual practices for domestic cleaning (Control group).
Number of subjects: 32
Study 19513845 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster intervention (SAFEChildren II)
Number of subjects: 196
Study 19513845 — intervention group
Group type: COMPARATOR
Intervention: Initial intervention only (SAFEChildren I)
Number of subjects: 196
Study 16409323 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl + Hybrid technique
Number of subjects: 180
Study 16409323 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl + NiTi rotary technique 4 mm shorter than the apex
Number of subjects: 180
Study 16409323 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl + NiTi rotary technique (Hero 642)
Number of subjects: 180
Study 16409323 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl + Hybrid technique
Number of subjects: 180
Study 16409323 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl + NiTi rotary technique 4 mm shorter than the apex
Number of subjects: 180
Study 16409323 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl + NiTi rotary technique (Hero 642)
Number of subjects: 180
Study 16409323 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% NaOCl + Hybrid technique
Number of subjects: 180
Study 16409323 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% NaOCl + NiTi rotary technique 4 mm shorter than the apex
Number of subjects: 180
Study 16409323 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% NaOCl + NiTi rotary technique (Hero 642)
Number of subjects: 180
Study 16409323 — intervention group
Group type: COMPARATOR
Intervention: sterile saline solution + Hybrid technique
Number of subjects: 180
Study 16409323 — intervention group
Group type: COMPARATOR
Intervention: sterile saline solution + NiTi rotary technique 4 mm shorter than the apex
Number of subjects: 180
Study 16409323 — intervention group
Group type: COMPARATOR
Intervention: sterile saline solution + NiTi rotary technique (Hero 642)
Number of subjects: 180
Study 15319024 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 251
Study 15319024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 11122095 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care anticoagulation management
Number of subjects: 0
Study 11122095 — intervention group
Group type: COMPARATOR
Intervention: Traditional hospital care-based provision
Number of subjects: 0
Study 9489432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NED) 8mg twice daily
Number of subjects: 16
Study 9489432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8384073 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose craniospinal radiation therapy (1800 cGy) plus chemotherapy (vincristine during RT, followed by vincristine, cisplatin, and lomustine for eight cycles every 6 weeks)
Number of subjects: 10
Study 8384073 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose craniospinal radiation therapy (1800 cGy) plus chemotherapy
Number of subjects: 10
Study 2936841 — intervention group
Group type: EXPERIMENTAL
Intervention: Written instructional booklet
Number of subjects: 0
Study 2936841 — intervention group
Group type: COMPARATOR
Intervention: Oral instruction from physician and clinical nurse specialist
Number of subjects: 0
Study 30039736 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 105
Study 30039736 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 105
Study 29115703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (SRT) at 200 mg
Number of subjects: 126
Study 29115703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 25709987 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg iv 2 minutes before induction of anesthesia
Number of subjects: 90
Study 25709987 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gabapentin 300 mg 1 hour before anesthesia
Number of subjects: 90
Study 25709987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 23683569 — intervention group
Group type: EXPERIMENTAL
Intervention: Phoxilium
Number of subjects: 15
Study 23683569 — intervention group
Group type: COMPARATOR
Intervention: Hemosol-B0
Number of subjects: 15
Study 21415104 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (500 μg/day)
Number of subjects: 502
Study 21415104 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (20.2 g/day)
Number of subjects: 502
Study 19615135 — intervention group
Group type: COMPARATOR
Intervention: Fluid resuscitation (group A)
Number of subjects: 89
Study 19615135 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration and fluid resuscitation (group B)
Number of subjects: 89
Study 16759540 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic model using serum protein fingerprint and support vector machine (SVM) with 3 biomarkers
Number of subjects: 81
Study 12752541 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular implant overdentures (IOD)
Number of subjects: 60
Study 12752541 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures (CD)
Number of subjects: 60
Study 11922148 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and oral hypoglycaemic drug (Daonil) therapy
Number of subjects: 35
Study 11922148 — intervention group
Group type: COMPARATOR
Intervention: Control group (thirty-four apparently healthy individuals)
Number of subjects: 35
Study 9725753 — intervention group
Group type: EXPERIMENTAL
Intervention: Halcion (triazolam) 0.375 mg p.o.
Number of subjects: 20
Study 9725753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8036521 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (MTX)
Number of subjects: 0
Study 2972540 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 75 micrograms (Group 1)
Number of subjects: 20
Study 2972540 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 75 micrograms with adrenaline 75 micrograms (Group 2)
Number of subjects: 20
Study 31707049 — intervention group
Group type: EXPERIMENTAL
Intervention: Zataria multiflora 5 mg/kg/day (Z5)
Number of subjects: 35
Study 31707049 — intervention group
Group type: EXPERIMENTAL
Intervention: Zataria multiflora 10 mg/kg/day (Z10)
Number of subjects: 35
Study 31707049 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 35
Study 31242139 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast water therapy
Number of subjects: 14
Study 31242139 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cold water immersion and active recovery
Number of subjects: 14
Study 31242139 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery
Number of subjects: 14
Study 31242139 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion
Number of subjects: 14
Study 31242139 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study 28233105 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable sutures
Number of subjects: 1147
Study 28233105 — intervention group
Group type: COMPARATOR
Intervention: Silk sutures
Number of subjects: 1147
Study 25217988 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling immobilization
Number of subjects: 21
Study 25217988 — intervention group
Group type: COMPARATOR
Intervention: No sling
Number of subjects: 21
Study 21246277 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing narratives about traumatic or stressful life events (prayers to God)
Number of subjects: 155
Study 21246277 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing narratives about traumatic or stressful life events (targeted at a person of their choice)
Number of subjects: 155
Study 21246277 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing narratives about traumatic or stressful life events (not targeted at anyone)
Number of subjects: 155
Study 21246277 — intervention group
Group type: COMPARATOR
Intervention: Control group writing about mundane experiences
Number of subjects: 155
Study 21246277 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma writing
Number of subjects: 155
Study 21309657 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg twice daily)
Number of subjects: 5599
Study 21309657 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (81 to 324 mg per day)
Number of subjects: 5599
Study 21309657 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 5599
Study 21309657 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 5599
Study 18587635 — intervention group
Group type: EXPERIMENTAL
Intervention: Valid study
Number of subjects: 248
Study 18587635 — intervention group
Group type: COMPARATOR
Intervention: Missing control group
Number of subjects: 248
Study 18587635 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal validity (valid vs. missing control group)
Number of subjects: 248
Study 18587635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological validity (high vs. low)
Number of subjects: 248
Study 18587635 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert evidence quality, expert credibility, and plaintiff credibility
Number of subjects: 248
Study 16958285 — intervention group
Group type: EXPERIMENTAL
Intervention: R + PBNT + CRR
Number of subjects: 30
Study 16958285 — intervention group
Group type: EXPERIMENTAL
Intervention: PBNT + CRR + R
Number of subjects: 30
Study 16958285 — intervention group
Group type: EXPERIMENTAL
Intervention: R + CSEB + CRR
Number of subjects: 30